Expression of PD-L1 and Prognosis in Breast Cancer: a Meta-analysis

Overview

Journal Oncotarget

Specialty Oncology

Date 2017 Apr 22

PMID 28430626

Citations 105

Authors

Minghui Zhang

Houbin Sun

Shu Zhao

Haihong Pu

Yan Wang

Qingyuan Zhang

Affiliations

Soon will be listed here.

Abstract

The associations between programmed cell death ligand 1 (PD-L1) and the prognosis of various cancers have always been a research topic of considerable interest. However, the prognostic value of PD-L1 in breast cancer patients remains a controversial subject. We aimed to assess the association between PD-L1 protein expression and clinicopathological features and the impact of this relationship on breast cancer survival. We performed a systematic search of the PubMed, EMBASE, and Cochrane Library databases to determine the correlations among PD-L1 expression, clinicopathological features and overall survival (OS). A total of 5 studies containing 2,546 cases were included in the analysis. The combined hazard ratio (HR) and its 95% confidence interval (CI) for OS were 1.76 (95% CI 1.09-2.82; P=0.02) for patients with tumors exhibiting PD-L1 overexpression. The pooled odds ratios (ORs) indicated that PD-L1 expression was associated with positive lymph node metastasis, higher histological grades, estrogen receptor (ER)-negativity, and triple-negative breast cancer (TNBC). Our findings indicate that PD-L1 expression is a promising biomarker for the prognosis of breast cancer, and may be helpful to clinicians aiming to select the appropriate immunotherapy for breast cancer.

Citing Articles

Towards the Prediction of Responses to Cancer Immunotherapy: A Multi-Omics Review.

Tao W, Sun Q, Xu B, Wang R Life (Basel). 2025; 15(2).

PMID: 40003691 PMC: 11856636. DOI: 10.3390/life15020283.

Expression of SIGLEC15 correlates with tumor immune infiltration, molecular subtypes, and breast cancer progression.

Lai H, Liu Y, Gong Y, Zong C, Zeng W, Chen H PLoS One. 2024; 19(11):e0313561.

PMID: 39541298 PMC: 11563486. DOI: 10.1371/journal.pone.0313561.

Trastuzumab Deruxtecan with Nivolumab in HER2-Expressing Metastatic Breast or Urothelial Cancer: Analysis of the Phase Ib DS8201-A-U105 Study.

Hamilton E, Galsky M, Ochsenreither S, Del Conte G, Martin M, De Miguel M Clin Cancer Res. 2024; 30(24):5548-5558.

PMID: 39405343 PMC: 11647201. DOI: 10.1158/1078-0432.CCR-24-1513.

Expression of PD-L1 in breast invasive lobular carcinoma.

Shin E, Kim H, Koo J PLoS One. 2024; 19(10):e0309170.

PMID: 39388456 PMC: 11466385. DOI: 10.1371/journal.pone.0309170.

Synergistic upregulation of PD‑L1 in tumor cells and CD39 in tumor‑infiltrating CD8 T cells leads to poor prognosis in patients with hepatocellular carcinoma.

Kang X, Zhao S, Lin S, Li J, Wang S Oncol Lett. 2024; 28(2):368.

PMID: 38933811 PMC: 11200054. DOI: 10.3892/ol.2024.14501.

References

Ishii H, Azuma K, Kawahara A, Yamada K, Imamura Y, Tokito T . Significance of programmed cell death-ligand 1 expression and its association with survival in patients with small cell lung cancer. J Thorac Oncol. 2014; 10(3):426-30. DOI: 10.1097/JTO.0000000000000414. View

Xu F, Feng G, Zhao H, Liu F, Xu L, Wang Q . Clinicopathologic Significance and Prognostic Value of B7 Homolog 1 in Gastric Cancer: A Systematic Review and Meta-Analysis. Medicine (Baltimore). 2015; 94(43):e1911. PMC: 4985428. DOI: 10.1097/MD.0000000000001911. View

Chowdhury S, Veyhl J, Jessa F, Polyakova O, Alenzi A, MacMillan C . Programmed death-ligand 1 overexpression is a prognostic marker for aggressive papillary thyroid cancer and its variants. Oncotarget. 2016; 7(22):32318-28. PMC: 5078015. DOI: 10.18632/oncotarget.8698. View

Mao Y, Li W, Chen K, Xie Y, Liu Q, Yao M . B7-H1 and B7-H3 are independent predictors of poor prognosis in patients with non-small cell lung cancer. Oncotarget. 2015; 6(5):3452-61. PMC: 4413666. DOI: 10.18632/oncotarget.3097. View

Guo Y, Yu P, Liu Z, Maimaiti Y, Wang S, Yin X . Prognostic and Clinicopathological Value of Programmed Death Ligand-1 in Breast Cancer: A Meta-Analysis. PLoS One. 2016; 11(5):e0156323. PMC: 4882023. DOI: 10.1371/journal.pone.0156323. View

Shin S, Jeon Y, Kim P, Cho Y, Koh J, Chung D . Clinicopathologic Analysis of PD-L1 and PD-L2 Expression in Renal Cell Carcinoma: Association with Oncogenic Proteins Status. Ann Surg Oncol. 2015; 23(2):694-702. DOI: 10.1245/s10434-015-4903-7. View

Zou W, Wolchok J, Chen L . PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations. Sci Transl Med. 2016; 8(328):328rv4. PMC: 4859220. DOI: 10.1126/scitranslmed.aad7118. View

Cooper W, Tran T, Vilain R, Madore J, Selinger C, Kohonen-Corish M . PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma. Lung Cancer. 2015; 89(2):181-8. DOI: 10.1016/j.lungcan.2015.05.007. View

Baptista M, Sarian L, Derchain S, Pinto G, Vassallo J . Prognostic significance of PD-L1 and PD-L2 in breast cancer. Hum Pathol. 2015; 47(1):78-84. DOI: 10.1016/j.humpath.2015.09.006. View

10.

Rosenbaum M, Bledsoe J, Morales-Oyarvide V, Huynh T, Mino-Kenudson M . PD-L1 expression in colorectal cancer is associated with microsatellite instability, BRAF mutation, medullary morphology and cytotoxic tumor-infiltrating lymphocytes. Mod Pathol. 2016; 29(9):1104-12. DOI: 10.1038/modpathol.2016.95. View

11.

Wu C, Zhu Y, Jiang J, Zhao J, Zhang X, Xu N . Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance. Acta Histochem. 2006; 108(1):19-24. DOI: 10.1016/j.acthis.2006.01.003. View

12.

Moher D, Liberati A, Tetzlaff J, Altman D . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg. 2010; 8(5):336-41. DOI: 10.1016/j.ijsu.2010.02.007. View

13.

Gentzler R, Hall R, Kunk P, Gaughan E, Dillon P, Slingluff Jr C . Beyond melanoma: inhibiting the PD-1/PD-L1 pathway in solid tumors. Immunotherapy. 2016; 8(5):583-600. DOI: 10.2217/imt-2015-0029. View

14.

Iacovelli R, Nole F, Verri E, Renne G, Paglino C, Santoni M . Prognostic Role of PD-L1 Expression in Renal Cell Carcinoma. A Systematic Review and Meta-Analysis. Target Oncol. 2015; 11(2):143-8. DOI: 10.1007/s11523-015-0392-7. View

15.

Gandini S, Massi D, Mandala M . PD-L1 expression in cancer patients receiving anti PD-1/PD-L1 antibodies: A systematic review and meta-analysis. Crit Rev Oncol Hematol. 2016; 100:88-98. DOI: 10.1016/j.critrevonc.2016.02.001. View

16.

Gradishar W, Anderson B, Balassanian R, Blair S, Burstein H, Cyr A . Invasive Breast Cancer Version 1.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2016; 14(3):324-54. DOI: 10.6004/jnccn.2016.0037. View

17.

Li Z, Dong P, Ren M, Song Y, Qian X, Yang Y . PD-L1 Expression Is Associated with Tumor FOXP3(+) Regulatory T-Cell Infiltration of Breast Cancer and Poor Prognosis of Patient. J Cancer. 2016; 7(7):784-93. PMC: 4860794. DOI: 10.7150/jca.14549. View

18.

Ali H, Glont S, Blows F, Provenzano E, Dawson S, Liu B . PD-L1 protein expression in breast cancer is rare, enriched in basal-like tumours and associated with infiltrating lymphocytes. Ann Oncol. 2015; 26(7):1488-93. DOI: 10.1093/annonc/mdv192. View

19.

Qin T, Zeng Y, Qin G, Xu F, Lu J, Fang W . High PD-L1 expression was associated with poor prognosis in 870 Chinese patients with breast cancer. Oncotarget. 2015; 6(32):33972-81. PMC: 4741818. DOI: 10.18632/oncotarget.5583. View

20.

Muenst S, Schaerli A, Gao F, Daster S, Trella E, Droeser R . Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer. Breast Cancer Res Treat. 2014; 146(1):15-24. PMC: 4180714. DOI: 10.1007/s10549-014-2988-5. View